The Riverside Company completed the investment in CRIO.

The Riverside Company, a private investor focused on the smaller end of the middle market, completed the investment in CRIO, a provider of eSource and other eClinical software for clinical trial sites, CROs and the pharmaceutical/biotech market. Financial terms were not disclosed. "Riverside has been an active investor in the eClinical software market over the last decade and we are excited to continue that commitment with an investment in CRIO. The CRIO team has done a fantastic job of creating a robust, feature-rich eSource product and is well-positioned to expand its offerings in the growing and underpenetrated clinical trial software industry," Loren Schlachet, Riverside Managing Partner.